Date: 2017-03-08
Type of information: Private placement
Company: Kite Pharma (USA - CA)
Investors:
Amount: $409.7 million
Funding type: private placement
Planned used:
- • On March 8, 2017, Kite Pharma announced the closing of its previously announced underwritten public offering of 4,750,000 shares of its common stock at a price to the public of $75.00 per share, as well as the exercise in full of the underwriters' option to purchase 712,500 additional shares.
- Including the option exercise, the total gross proceeds to Kite from the offering are expected to be approximately $409.7 million , before deducting the underwriting discounts and commissions and estimated offering expenses. The closing of the option exercise is expected to occur on or about March 10, 2017 , subject to customary closing conditions.
Others:
- • On March 8, 2017, Kite Pharma announced the closing of its previously announced underwritten public offering of 4,750,000 shares of its common stock at a price to the public of $75.00 per share, as well as the exercise in full of the underwriters' option to purchase 712,500 additional shares. Including the option exercise, the total gross proceeds to Kite from the offering are expected to be approximately $409.7 million , before deducting the underwriting discounts and commissions and estimated offering expenses. The closing of the option exercise is expected to occur on or about March 10, 2017 , subject to customary closing conditions.
• On March 2, 2017, Kite Pharma announced the commencement of an underwritten public offering of 4,750,000 shares of its common stock. In addition, Kite has granted the underwriters of the offering a 30-day option to purchase up to an additional 712,500 shares of its common stock. All shares of common stock to be sold in the offering will be sold by Kite. Jefferies LLC is acting as sole book-running manager for the offering.
Therapeutic area:
Is general: Yes
